Chronic Graft vs Host Disease Clinical Trial
Official title:
Phase II Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in Patients Who do Not Obtain Complete Remission With Ruxolitinib
Phase II clinical trial to assess the efficacy of donor regulatory enriched T cells in steroid-refractory chronic graft versus host disease patients who did not obtain complete remission under treatment with ruxolitinib
A number of 15 patients will be included to assess the efficacy of donor regulatory enriched T cells in steroid-refractory chronic graft versus host disease patients who did not obtain complete remission after 12 weeks of treatment with ruxolitinib. The doses of Treg-enriched cells will be 2x10^6 cells/kg. Survival at 1 year after Treg infusion will be represented based on the clinical data with Kaplan Meier curves. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03683498 -
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease
|
Phase 1 | |
| Completed |
NCT01221766 -
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
|
N/A | |
| Active, not recruiting |
NCT02067832 -
Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
|
||
| Active, not recruiting |
NCT02759731 -
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Terminated |
NCT04852692 -
A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants
|
||
| Recruiting |
NCT02669251 -
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 |